Randomized, controlled, open label, multi-center phase III trial comparing the safety and antiviral activity of a protease-containing regimen (d4T/ddI/IDV/RTV) [stavudine + didanosine + indinavir + ritonavir] versus a protease-sparing regimen (d4T/ddI/EFV) [stavudine + didanosine + efavirenz] and the ability of interleukin-2 to purge HIV from latent stores in patients with acute/early HIV infection

Trial Profile

Randomized, controlled, open label, multi-center phase III trial comparing the safety and antiviral activity of a protease-containing regimen (d4T/ddI/IDV/RTV) [stavudine + didanosine + indinavir + ritonavir] versus a protease-sparing regimen (d4T/ddI/EFV) [stavudine + didanosine + efavirenz] and the ability of interleukin-2 to purge HIV from latent stores in patients with acute/early HIV infection

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2013

At a glance

  • Drugs Efavirenz (Primary) ; Indinavir (Primary) ; Ritonavir (Primary) ; Abacavir; Didanosine; Interleukin-2; Stavudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Sep 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Sep 2008 Planned initiation date (Sep 2009) added as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top